Decrypt genomic data to bring out new personalized treatments.
Measure DNA repair deficiency (DRD) by analysing genomic instability concentration.
Increasing treatment effectiveness
Protecting patients from deleterious treatments
Reducing costs of clinical trials and R&D pipelines
Accelerate drug pipelines, increase clinical trials
Pharmaceutical and Biotech Industries
Need: In-depth analysis of genomic profiles for new drug development.
Solutions: NGS data analysis services, drug response signature.
Healthcare Professionals
Need: Personalization of treatments for better therapeutic effectiveness.
Solutions: Patient stratification, therapy response prediction.
The value of measuring genomic instability in complex cancers
Targeted cancers with high levels of genomic instability:
Magic X software and applications
Drug Signature of Response for personalized medicine
Functionality: Genomic Instability Analysis
Measure of genomic instability concentration in our biomarkers and genomic intervals
Measure of genomic instability concentration in genomic intervals of your choice
Predict probabilities of drugs responses
Benefits: Selecting personalized treatments to increase therapeutic success.
Patient Stratification for clinical trials
Functionality: Analyzing the relationship between genomic instability and clinical outcome.
Upload you sequencing data
Compute genomic instability concentration biomarkers
Stratify your cohort
Get patients inclusion and exlusion criteria
Benefits: Selecting patients responding to chemotherapy
Patient Stratification for clinical trials
Functionality: Analyzing the relationship between genomic instability and clinical outcome.
Upload you sequencing data
Compute genomic instability concentration biomarkers
Stratify your cohort
Get patients inclusion and exlusion criteria
Benefits: Selecting patients responding to chemotherapy
Magic X, how does it work ?
#1 Genomic data
#2 Concentration calculation
#3 Population stratification
#4 Magic X report
Magic X as a Service & Magic X License
Magic X as a Service
In Preclinical Studies: Benefit from our cutting-edge genomic expertise in preclinical research.
As part of your preclinical studies, Magic Genomix supports you in evaluating the best biomarkers from genomic data and optimizing your new drug pipelines.
Genomic data analysis (whole genome, RNA, and exome) for the identification of structural variants.
Identification of new treatments sensitivity and resistance signatures.
Cohort stratification based on genomic instability.
Do you have a project?
Magic X License
In Clinical Studies:
Integrate Magic X software into your research (license for use).
Would you like to take advantage of the full power of Magic X?
The stratification of metastatic risk in leiomyosarcoma
Chemotherapy is not the standard of treatment in leiomyosarcoma and no clinical trial has ever demonstrated therapeutic benefice. Leiomyosarcoma is a genetically complex type of sarcoma.
By exlporing the concentration of genomic instability in iTRAC (Transcription associated chromosomal instability index) biomarkers, we have shown that patients treated with chemotherapy in low iTRAC groupe have increased metastatic risk compared to not treated patients.
Medium and High iTRAC patients treated with chemotherapy has no stastically significant difference in metastatic risk compared to not treated patients.
Our team
Frédéric Nahon,
CEO
Ataaillah Benhaddou, CSO
Patrick Kermaïdic,
COO
Mohamed Benhaddou, CTO
They support us
Contact us
At Magic Genomix, we are passionate about innovation and excellence in the field of genomics. Whether you have questions about our services, need more information about our products, or want to discuss a potential collaboration, we are here to help. Fill out the form below, and our team will get back to you as soon as possible. We look forward to hearing from you!
